Clinical Trial: Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)

U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07864207) titled 'Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)' on Sept. 29.

Brief Summary: Phase 1/2 clinical trial is to evaluate the safety, pharmacokinetics and pharmacodynamics of escalating doses of IDP-121 combined with chemotherapy in patients with advanced unresectable/metastatic SCLC that have progressed after 1st line platinum- based chemotherapy, considering the role of MYC amplification in the development of platinum resistance.

Study Start Date: July 28

Study Type: INTERVENTIONAL

Condition: Small Cell Lung Cancer ( SCLC )

Intervention: D...